Leriglitazone
Phase 3Small molecule
Leriglitazone is one of 9 small molecule programs targeting Adrenoleukodystrophy. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
11 competitors in Adrenoleukodystrophy
#DrugCompanyPhaseTrials
1Mirapex
Boehringer IngelheimApproved
Busulfex
Akero TherapeuticsApproved
Cytoxan
BBaxter Healthcare Corporation
Approved
Leriglitazone
MMinoryx Therapeutics, S.L.
Phase 3
Thalomid
Bristol-Myers SquibbPreclinical
Mesenchymal Stem Cells
JJiangsu Topcel-KH Pharmaceutical Co., Ltd.
Phase 1
Sobetirome
NNeuroVia, Inc.
Phase 2
Interferon-Beta
BiogenPreclinical
Lorenzo's Oil
UUniversity of Minnesota
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Leriglitazone. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- MMinoryx Therapeutics, S.L.